i-Lumen i-SIGHT Feasibility Study Results Presented at CTS Retina 2026
Randomized, sham-controlled feasibility trial of noninvasive bioelectric identified signals of potential improvement in visual function, retinal electrophysiology, and structural biomarkers in dry AMD BLOOMINGTON, Minn., Nov. 10, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc., a...
Covered in this story
Call it yourself
No calls on $CTS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Cts Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.